AMRX — Amneal Pharmaceuticals, Inc.

Is AMRX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Overbought As of November 17, 2026

Amneal Pharmaceuticals, Inc. (AMRX) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $21.12. The rating moved from Oversold to Overbought on November 9, 2026.

See all overbought Healthcare stocks →

AI analysis

Amneal Pharmaceuticals, Inc. (AMRX) combines a broad generics ANDA base with specialty product channels that produce steady cash flow but face secular pricing pressure and competitive headwinds. Near-term support is likely from defensive sector flows into pharma and stable prescription volumes, while upside catalysts would include successful new launches, meaningful margin improvement from cost programs, or favorable M&A outcomes. Key vulnerabilities are regulatory changes affecting reimbursements, elevated leverage and refinancing needs, and execution risk around manufacturing and integration. Expect range-bound trading with episodic volatility tied to earnings, product approvals/launches, or material corporate events.

Key factors

  • Diversified generics and specialty product portfolio providing recurring revenue and cash flow
  • Established ANDA footprint and specialty/infusion channels that help stabilize prescriptions through cycles
  • Defensive sector flows into healthcare and pharma reduce downside volatility in the near term
  • Operational integration and cost efforts could incrementally expand margins if execution remains smooth
  • Limited fresh public catalysts or positive social/EDGAR signals in the immediate window; earnings/announcements will drive near-term moves

Risks

  • Prolonged generic pricing pressure and heightened competition on key ANDAs compressing revenue and margins
  • Regulatory risk from CMS anti-fraud/program-integrity measures and broader payer reimbursement dynamics
  • Balance-sheet leverage and refinancing risk that could limit strategic flexibility and increase interest expense
  • Manufacturing or quality issues that could trigger recalls, supply disruptions or FDA scrutiny
  • Industry consolidation and larger-cap acquisitive activity that could pressure mid‑cap pricing power or force asset divestitures
  • Legal and IP litigation risk typical for generic/specialty pharma franchises

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for AMRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.